Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2013. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of a specific internal transaction rather than a financial performance report.
Material Changes
The filing details a revaluation of the cash element of a notional investment held within the US Retirement Savings Plan, which is notionally held in GSK American Depositary Shares (ADSs). On April 26, 2013, at a price of $52.16 per ADS, the following increase in notional allocation occurred:
- Dr M M Slaoui (Director/PDMR): No change in ADS allocation.
- Dr K Slaoui (Connected Person): Increase of 3 ADSs.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the specific transaction notification described above.
Key Facts for Investor Verification
- Verify the impact of the US Retirement Savings Plan revaluation on executive compensation structures.
- Confirm the current market price of GSK ADSs relative to the $52.16 transaction price cited in April 2013.
- Review the full Disclosure and Transparency Rule 3.1.4R(1)(a) and (c) compliance details for Dr K Slaoui.